Dr. Callahan presented a talk on OA and comorbidities/mortality as part of a discussion panel focused on impact of OA; prevalence, risk factors, societal burden, and unmet need.
The one day meeting, held on May 16th in Washington, D.C., was hosted by the Osteoarthritis Research Society International (OARSI). The goal of the meeting was to present information for the FDA to use in assessing the impact of OA, and to provide an open dialog for participants to discuss issues surrounding the development of therapies that treat the progression of the disease, as well as the need for new therapies being made available to patients.
The title of the meeting was: Expedited Clinical Programs and Study Designs for Osteoarthritis Structure Modifying Therapies.
To learn more about the meeting and specific topics discussed, use this link.